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The  toxic  potencies  of ﬁve  goldenseal  alkaloid  constituents  were  compared.
Berberine  appeared  to  be  the  most  potent  DNA  damage  inducer.
DNA  damage  was  directly  associated  with  the  inhibitory  effect  of  Topo  II.
The  extent  of DNA  damage  was  positively  correlated  to the berberine  content  in goldenseal  products.
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a  b  s  t  r  a  c  t
Goldenseal  has been  used  for the  treatment  of  a wide  variety  of  ailments  including  gastrointestinal
disturbances,  urinary  tract disorders,  and  inﬂammation.  The  ﬁve  major  alkaloid  constituents  in goldenseal
are berberine,  palmatine,  hydrastine,  hydrastinine,  and  canadine.  When  goldenseal  was  evaluated  by  the
National Toxicology  Program  (NTP)  in  the  standard  2-year  bioassay,  goldenseal  induced  an  increase  in
liver tumors  in rats  and  mice;  however,  the  mechanism  of  goldenseal-associated  liver carcinogenicity
remains  unknown.  In this  study,  the  toxicity  of the  ﬁve  goldenseal  alkaloid  constituents  was  characterized,
and  their  toxic  potencies  were  compared.  As  measured  by  the  Comet  assay  and  the  expression  of  -
H2A.X,  berberine,  followed  by  palmatine,  appeared  to be the  most  potent  DNA damage  inducer  in humanNA damage
oldenseal
-H2A.X
opoisomerase
hepatoma  HepG2  cells.  Berberine  and  palmatine  suppressed  the  activities  of both  topoisomerase  (Topo)
I  and  II. In berberine-treated  cells,  DNA  damage  was  shown  to be  directly  associated  with  the  inhibitory
effect  of  Topo  II, but  not  Topo  I  by silencing  gene  of Topo  I or Topo  II.  In addition,  DNA  damage  was
also  observed  when  cells  were  treated  with  commercially  available  goldenseal  extracts  and  the  extent
of DNA  damage  was  positively  correlated  to the  berberine  content.  Our  ﬁndings  suggest  that the Topo  II
tribut
The Ainhibitory  effect  may  con
© 2013 
. Introduction
Goldenseal (Hydrastis canadensis) is available in a wide array
f herbal products on the international market. According to the
merican Herbal Products Association (AHPA), over 90% of its
ember businesses sell goldenseal-containing products (CITES,
997; NatureServe), with sales close to $50 million annually in
he United States alone (Govindan and Govindan, 2000). Phar-
acological studies of goldenseal have focused on its alkaloid
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uthors. Published by Elsevier Ireland Ltd. 
constituents, particularly on berberine. Because of their purported
beneﬁcial effects, goldenseal and berberine have been used for a
wide range of remedies, both internally and externally, for their
anti-catarrhal, anti-inﬂammatory, anti-diabetes, antiseptic, astrin-
gent, bitter tonic, laxative, and muscular stimulant properties
(Hamon, 1990; NTP, 2009).
Goldenseal was nominated to the National Toxicology Program
(NTP) for toxicity evaluation based on the potential high level of
human exposure and the lack of carcinogenicity data. The NTP has
conducted 2-year carcinogenicity bioassays on goldenseal powder
in rodents. The primary ﬁnding was  that goldenseal increases the
incidence of liver tumors in rats and mice (Dunnick et al., 2011):
as summarized in an NTP report (NTP, 2009), “there was clear evi-
Open access under CC BY-NC-ND license.dence of carcinogenic activity of goldenseal root powder in male
F344/N rats based on the increased incidences of hepatocellular
adenoma and carcinoma. There was  clear evidence of carcinogenic
activity of goldenseal root powder in female F344/N rats based
NC-ND license.
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n the increased incidence of hepatocellular adenoma. There was
ome evidence of carcinogenic activity of goldenseal root powder in
ale B6C3F1 mice based on the increased incidences of hepatoblas-
oma and multiple hepatocellular adenomas”. Since the mechanism
f goldenseal-associated liver carcinogenicity is unknown, it is of
reat interest to investigate the potential mechanisms that may
ontribute to its carcinogenicity.
DNA topoisomerases are evolutionally conserved nuclear
nzymes that are able to break and rejoin the sugar-phosphate
ackbone of DNA and modulate the topology of DNA helix
Champoux, 2001; Vos et al., 2011). Cells have two types of DNA
opoisomerases: Topo I acts by introducing a transient breakage
f a single strand of DNA, while Topo II transiently breaks both
NA strands; both types of breaks are essential for DNA replication
uring cell proliferation. Inhibition of topoisomerase activity also
esults in signiﬁcant genotoxicity and jeopardizes cellular functions
McClendon and Osheroff, 2007).
Unrepaired DNA breaks trigger chromosomal translocations,
ultiloci deletions, and loss of heterozygosity, all of which
ontribute to carcinogenicity. Clinically, an association between
xposure to topoisomerase inhibitors and secondary leukemia has
een reported (Boos and Stopper, 2000; Hijiya et al., 2009; Seiter
t al., 2001; Tebbi et al., 2007). Previous studies have indicated
hat berberine, berberubine (one of berberine’s metabolites), and
ome protoberberine alkaloids could inhibit the activities of topoi-
omerases (Kang and Chung, 2002; Kettmann et al., 2004; Kim et al.,
998; Kobayashi et al., 1995; Li et al., 2000; Qin et al., 2007); how-
ver, it remains unclear if the inhibitory effect occurs on Topo I or
I or both.
In the present study, we examined ﬁve goldenseal constituents
or their inhibitory effect on Topo I and Topo II in a cell free
ystem and for their ability to induce DNA damage in HepG2
ells. Our results indicate that berberine and, to a lesser degree,
almatine, cause profound DNA strand breakage. Berberine and
almatine inhibit the activity of both Topo I and II. In addi-
ion, berberine modulates the G1 and G2/M checkpoint responses.
lso, in HepG2 cells, the Topo II inhibitory effect of berberine is
nvolved in generating excessive DNA damage which may  con-
ribute to berberine- and goldenseal-induced genotoxicity and
umorigenicity.denseal constituents.
2. Materials and methods
2.1. Chemicals and reagent
Berberine was  purchased from TCI America (Portland, OR); palmatine, hydras-
tine, and hydrastinine were from Sigma–Aldrich (St. Louis, MO); canadine (Fig. 1)
was purchased from Ryan Scientiﬁc, Inc. (Mount Pleasant, SC). Fetal bovine serum
(FBS) was  obtained from Atlanta Biologicals (Lawrenceville, GA). William’s E
medium, penicillin, streptomycin, hydrogen peroxide (H2O2), and dimethysulfoxide
(DMSO) were purchased from Sigma–Aldrich. Puriﬁed human Topo I and II enzymes
and Topo I and II assay kits were from TopoGen, Inc. (Port Orange, FL).
2.2. Cell culture
The human hepatoma cell line HepG2 was obtained from the American Type Cul-
ture  Collection (ATCC; Manassas, VA). The cells were grown in Williams’s E medium
supplemented with 10% FBS and antibiotics (50 U/ml penicillin and 50 g/ml strep-
tomycin) at 37 ◦C in a humidiﬁed atmosphere with 5% CO2. Unless otherwise
speciﬁed, HepG2 cells were seeded at a concentration of 2–5 × 105 cells/ml in vol-
umes of 100 l in the wells of 96-well plates, in volumes of 5 ml in 60 mm tissue
culture plates, or in volumes of 10 ml in 100 mm tissue culture plates. Cells were
cultured for about 24 h prior to treatment with the indicated concentrations of
goldenseal constituents or the vehicle control, DMSO (ﬁnal concentration 0.1%).
The  293T cell line used for lentivirus packaging was  purchased from Biosettia
(San Diego, CA) and maintained in Dulbecco’s Modiﬁed Eagle Medium (DMEM) sup-
plemented with 10% FBS in the presence of 1 mM sodium pyruvate, non-essential
amino acids, and antibiotics.
2.3. Vector construction and stable cell lines establishment
Two  speciﬁc target sites for silencing of human Topo I and two  sites for
silencing of Topo II were identiﬁed using RNAi Designer available at the Invitrogen’s
website (https://rnaidesigner.invitrogen.com/rnaiexpress/index.jsp). Small hairpin
RNA  (shRNA) sequences were designed according to the structure of a Doxcyclin
(Dox) inducible shRNA lentiviral expression vector (Biosettia Inc., San Diego,
CA). The following shRNAs-encoding DNA oligos containing inner palindromic
sequences were synthesized (Biosythesis, Inc., Lewisville, Texas): sh1-topo I
(5′-AAAAGCATAGCAACAGTGAACATTTGGATCCAAATGTTCACTGTTGCTATGC-3′) and
sh2- topo I (5′-AAAAGGATGATGCTGATTATAAATTGGATCCAATTTATAATCAGCATCAT
CC-3′) were used for silencing of Topo I. sh1-topo II (5′-AAAAGGAAACAGCCAGTA
GAGAATTGGATCCAATTCTCTACTGGCTGTTTCC-3′) and sh2-topo II (5′-AAAAGCCA
TCCACTTCTGATGATTTGGATCCAAATCATCAGAAGTGGATGGC-3′) were used for
silencing of Topo II. The scramble shRNA (5′-AAAAGCTACACTATCGAGCAATTTT
GGATCCAAAATTGCTCGATAGTGTAGC-3′), which did not contain signiﬁcant homol-
ogy  to known genes, was used as control in silencing experiments. DNA oligos
were annealed to each other to form a double-stranded oligo and then ligated into
linearized vector pLV-H1TetO-GFP-Bsd following the manufacturer’s instructions
(Biosettia Inc.). The generated lenti-shRNA vectors and viral packaging system
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with 100 M berberine at 2 h and was dramatically elevated in cells6 S. Chen et al. / Toxicolo
ere co-transfected into 293T cells to produce lenti-shRNA viral stocks. HepG2
ells were then infected with lentivirus carrying scramble control shRNA or shRNA
argeting either Topo I or II transcript, followed by colony selection in the presence
f  6 g/ml Blasticidin (Bsd) to generate a polyclone of HepG2 cells with stable
xpression of Dox-inducible scramble control or stable sh-topo I or sh-topo II
xpression. In total, ﬁve stable cell lines were generated, namely, SC (scramble
ontrol), sh1-topo I (Topo I silencing cell line 1), sh2-topo I (Topo I silencing cell
ine 2), sh1-topo II (Topo II silencing cell line 1), and sh2-topo II (Topo II silencing
ell  line 2).
.4. Cell cycle analysis
Cells (1 × 106/ml) were trypsinized and ﬁxed on ice in 1 ml 70% cold ethanol
or  1 h. After washing twice with cold PBS, cells were resuspended in 0.25 ml  of
ce-cold PBS containing 0.2 g/l  RNase A (Qiagen, Valencia, CA) and incubated at
7 ◦C for 1 h. Propidium iodide (PI; Sigma–Aldrich) was  added to the cells at a ﬁnal
oncentration of 10 g/ml and the cells were further incubated at 4 ◦C overnight. The
nalysis of DNA content (cell cycle analysis) was performed the following day on a
ACSCanto II ﬂow cytometer (BD Biosciences, San Jose, CA). Data were acquired using
ACSDiva software (BD Biosciences) and the cell cycle distribution was  determined
sing ModFit LT 2.0 (Verity Software House Inc., Topsham, ME).
.5. High-performance liquid chromatography (HPLC) determination
HPLC analysis of berberine and other goldenseal alkaloids content in commercial
oldenseal products was  performed using a refrigerated Varian 920LC system. A
henomenex (Torrance, CA. USA) Luna C18(2) (5 m particles 100 A pore) HPLC
olumn (150 mm × 3 mm),  equipped with a Phenomenex Secure Guard cartridge,
as  used. The mobile phase composition for the ﬁrst 3.5 min  was  10% methanol and
0% of an aqueous solution of 0.1% formic acid. The methanol percentage increased
o  20% at 5 min, 30% at 10 min, 35% at 15 min, and held at 35% for 5 min  before
eturning to the initial 10% at 22 min. An equilibration time of 18 min was included.
he ﬂow rate was  initially 0.4 ml/min and was increased to 0.6 ml/min over 0.5 min
nd held at that rate for 40.5 min.
The commercial goldenseal extracts were initially diluted 1/100 in 0.1% formic
cid running buffer and a mix  containing the ﬁve standards was included with each
un.  Berberine was  detected with a Varian PDA (wavelength range from 200 to
50  nm 4 nm slits) and eluted at approximately 17 min  under these conditions. The
hromatogram was monitored at wavelengths of 265 and 347 nm. The other elution
imes were: hydrastinine, approximately 3 min; hydrastine, approximately 4.0 min
a  second peak was present in the hydrastine standard, with an elution time of
pproximately 12 min); canadine, approximately 15.5 min; and palmatine, approx-
mately 18 min. Linear regression was performed for calculating concentration of
erberine in each extract.
.6. Assay of Topo I-mediated relaxation of supercoiled plasmid
The Topo I enzyme assay was  conducted by measuring the relaxation of negative
upercoiled plasmid DNA pBR322 (TopoGen). A 20 l mixture reaction containing
0  mM Tris HCl (pH 7.9), 150 mM NaCl, 1 mM EDTA, 0.1 mM spermidine, 0.1% BSA, 5%
lycerol, and 250 ng supercoiled plasmid DNA was  incubated with or without the
est compound (berberine or other goldenseal constituents). Camptothecin (CPT)
as  used a positive control. The enzyme reaction was initiated by addition of 2
nits of puriﬁed human Topo I (TopoGen) at 37 ◦C for 30 min.
.7. Assay of Topo II-mediated kDNA decatenation
Topo II enzymatic activity was assayed by measuring decatenation of kinetoplast
NA (kDNA) (TopoGen). A total of 20 l reaction containing 50 mM Tris HCl (pH 8.0),
50  mM NaCl, 10 mM MgCl2, 2 mM ATP, 0.5 mM DTT, 30 g/ml BSA, and 125 ng kDNA
as  incubated with or without test compound; the enzyme reaction was initiated
y  the addition of 1 unit puriﬁed human Topo II (TopoGen) at 37 ◦C for 30 min.
.8. Comet assay
The Comet assays were performed under alkaline condition to detect DNA sin-
le and double strand breaks. HepG2 cells were seeded in a 100 mm tissue culture
late, and the cells were exposed to goldenseal constituents up to 50 M,  vehicle
ontrol (0.1% DMSO), or positive control (200 M H2O2 or 0.1 g/ml 4-NQO) for 2 h
r  6 h. Cells were washed twice with PBS (Ca2+ Mg2+ free), collected by trypsin diges-
ion, and resuspended in PBS (Ca2+ Mg2+ free) at a concentration of 1 × 105 cells/ml.
hen 50 l of cell suspension was  combined with 500 l molten 0.75% low melting
oint agarose (Trevigen Inc., Gaithersburg, MD), and 50 l was  immediately pipetted
nto a Trevigen CometSlideTM. After solidiﬁcation, the slides were immersed in 4 ◦C
rechilled lysis solution for 1 h. The slides were then placed in a electrophoresis tank
lled with ice-cold electrophoretic buffer (200 mM NaOH and 1 mM EDTA, pH > 13)
or  1 h to allow DNA unwinding. Electrophoresis was  performed in the same buffer
or  45 min  at 33 V and 260 mA.  After electrophoresis, the slides were removed and
insed by placing them in ice-cold ddH2O twice, 5 min  each time, and then in ice-coldters 221 (2013) 64– 72
70% ethanol for 5 min, then stained with 100 l of SYBR® Gold dye (Life technolo-
gies, Grand Island, NY) just before analysis. The slides were scored using an imaging
analysis system consisting of a Nikon 501 ﬂuorescent microscope (Melville, NY) and
a  Comet Assay IV digital analysis system (Perceptive Instruments Ltd., Edmunds,
UK). A total of 100 cells per sample was scored and data was pooled together as an
endpoint. The percentage of DNA in tails was used as the parameter for evaluation
of  DNA breakage.
2.9. RNA isolation and real-time TaqMan PCR assay
Total RNA from cells was isolated using the RNeasy system (Qiagen, German-
town MD). Determination of quality and quantity was as described previously (Li
et  al., 2011).
Real-time TaqMan PCR assays for Topo I and Topo II were conducted using
a  Bio-Rad CFX96TM Real-Time PCR Detection System (Bio-Rad Laboratories, Her-
cules, CA). Reactions were prepared according to the manufacturer’s instructions for
TaqMan® Gene Expression Assays (Applied Biosystems by Life Technologies, Foster
City, CA). TaqMan assays were Topo I (Hs00243257 m1), Topo II (Hs00172214 m1),
and endogenous control -actin (ACTB, Hs01060665 g1). Assays were run with
Applied Biosystems’ Universal Master Mix  (2×)  without AmpErase UNG, using uni-
versal cycling conditions (10 min  at 95 ◦C; 15 s at 95 ◦C, 1 min 60 ◦C, 40 cycles). Data
normalization and analysis were conducted as described previously (Guo et al.,
2009).
2.10. Western blot analysis
Cells were grown and treated with berberine and commercial goldenseal
extracts in 100 mm tissue culture plates or 60 mm tissue culture plates. Standard
Western blots were performed using antibodies against total H2A.X, -H2A.X,
p21Waf1/Cip1, p-ChK1 (Ser-345), p-ChK2 (Thr-68) (Cell Signaling Technology, Dan-
vers, MA), and -actin (internal control, Santa Cruz Biotechnology, Santa Cruz, CA)
followed by a secondary antibody conjugated with horseradish peroxidase (HRP).
The intensity of each band was  quantiﬁed with UVP BioSpectrum Imaging System
(UVP, LLC; Upland, CA).
2.11. Statistical analysis
Data are presented as mean ± standard deviation (SD) of at least three indepen-
dent experiments. Analyses were performed using GraphPad Prism 5 (GraphPad
Software, San Diego, CA). Statistical signiﬁcance was  determined by one way analy-
sis  of variance (ANOVA) followed by the Dunnett’s tests for pairwise-comparisons or
two way ANOVA followed by the Bonferroni post-test. The difference was considered
statistically signiﬁcant when p < 0.05.
3. Results
3.1. Berberine induces DNA damage in HepG2 cells
To assess DNA damaging potential of goldenseal constituents, a
single-cell gel electrophoresis procedure, often termed the “Comet
assay”, was  used. HepG2 cells were treated with berberine, pal-
matine, hydrastine, hydrastinine, or canadine at 50 M for 24 h. Of
the ﬁve constituents tested, berberine caused a strong induction
of Comet tails and palmatine caused moderate induction, whereas
the other three compounds did not increase the tail intensity (data
not shown). Berberine-induced DNA strand breakage was further
examined at various berberine concentrations. As shown in Fig. 2A,
treatment with berberine resulted in a dose- and time-dependent
increase in the Comet tail intensity. Signiﬁcant DNA  damage was
observed as early as at 2 h; a 16.6% tail intensity was observed with
6.25 M berberine treatment, whereas only a 7.7% tail intensity
appeared with the control. At 6 h and 24 h, berberine caused exten-
sive DNA breakage starting at 3.125 M with tail intensities of 14.6%
and 17.9%, respectively.
The presence of DNA strand breaks was  conﬁrmed by measuring
histone H2A.X phosphorylation at Serine139 (-H2A.X), a hallmark
of DNA strand breakage in cells (Rogakou et al., 1998). As shown
in Fig. 2B, phosphorylated -H2A.X was  detected in cells treatedtreated at 24 h. The levels of total H2A.X protein were not different
between berberine treated cells and the vehicle control, indicating
that berberine is critical for the efﬁcient induction of phosphate
H2A.X (-H2A.X) after DNA damage.
S. Chen et al. / Toxicology Letters 221 (2013) 64– 72 67
Fig. 2. Berberine induces DNA damage in HepG2 cells. HepG2 cells were exposed to increased concentrations (0, 3.125, 6.25, 12.5, 25, 50, or 100 M) of berberine for 2, 6,
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rials;  * p < 0.05, ***p < 0.001). (B) Total cellular protein was extracted at the indicate
y  Western blotting. -actin was used as a loading control. Similar results were obt
.2. Commercial goldenseal products cause DNA damage in
epG2 cells and the extent of the damage correlates with
erberine content
Next, whether or not eight commercial goldenseal extract prod-
cts produce DNA damage in liver cells was  determined. We
valuated DNA damage capacity using -H2A.X as the indicator of
NA strand breaks. Berberine content in each goldenseal extract
anged from 5.3 to 49.5 mM as determined by HPLC (Fig. 3A).
epG2 cells were exposed to a constant volume of eight goldenseal
xtracts on 100 mm dishes for 6 h (20 l in 10 ml  medium). The
esulting berberine ﬁnal concentrations in cultures were from 10.6
o 99 M.  As depicted in Fig. 3B, Western blot analysis showed that
-H2A.X was induced by most extracts, and the levels of -H2A.X
ere dependent on berberine concentration, i.e. the higher the
erberine content in the goldenseal extract, the stronger the induc-
ion of -H2A.X. For example, Extract #1 (E1), with a ﬁnal berberine
oncentration of 99 M in the cell culture medium, showed the
reatest -H2A.X induction, whereas Extract #8 (10.6 M berber-
ne) did not induce a detectable increase in -H2A.X (Fig. 3B). A
ig. 3. Commercial goldenseal extracts induce DNA damage and the extent of DNA dama
he  berberine concentrations of eight commercially available goldenseal products as mea
xtracts for 6 h in 10 ml  culture medium and analyzed for -H2A.X by Western blotting
etween the expression levels of -H2A.X and the concentration of berberine in eight com
n  (B), of -H2A.X normalized by -actin. The band intensities in the Western blots we
eparate experiments.ntrations and time points. Data are the means ± S.D. (n = 100 cells in each of three
s, and levels of phosphorylated (-H2A.X) and total histones H2A.X were detected
 from three independent experiments.
linear relationship was observed when densitometric quantita-
tion of the levels of normalized -H2A.X expression (the ratio of
the -H2A.X to -actin) were plotted against berberine contents
in the eight commercial goldenseal extracts (correlation coefﬁ-
cient = 0.9758 and p < 0.001) (Fig. 3C). These results indicate that
the goldenseal products induce DNA damage in liver cell cultures
and DNA damage may  be attributed to the berberine contained in
them.
3.3. Berberine induces cell cycle arrest and activates checkpoints
related protein in HepG2 cells
HepG2 cells were treated with various concentrations of berber-
ine for 24 h (under these conditions, no signiﬁcant cytotoxicity was
observed with the lactate dehydrogenase (LDH) assay as described
previously (Li et al., 2012), Harker et al., 1991; Supplemental Fig. 1),
and cell cycle proﬁles were analyzed by measuring the DNA  con-
tent. Flow cytometric cell cycle distribution analysis indicated that
the percentage of cells in S-phase decreased with increasing con-
centration of berberine, with parallel increases in the percentage
ge correlates with berberine content in the extracts. (A) The bar graph represents
sured by HPLC. (B) HepG2 cells were treated with 20 l of commercial goldenseal
. -actin was used as a loading control. (C) Statistical analysis of the relationship
mercial goldenseal extracts. Plot represents quantitative expression levels, shown
re determined by Image J software. Data were expressed as means ± S.D. of three
68 S. Chen et al. / Toxicology Letters 221 (2013) 64– 72
Fig. 4. Effects of berberine on cell cycle of HepG2 cells. (A) Flow cytometric analysis for cell cycle distribution. Histograms shown are DNA content analyses for HepG2 cells
treated with the indicated concentrations of berberine for 24 h. Treated cells were stained with propidium iodide (PI) and processed for cell cycle analysis. (B) The bar graph
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hase of DMSO-treated cells. (C) Expression of cell cycle checkpoint-related proteins
ells  were lysed and subjected to Western blotting analyses with antibodies agains
f cells in G1-phase and G2/M-phase, compared to DMSO-treated
ells (Fig. 4A and B). These results implied that berberine blocks cell
ycle progression by arresting cells in G1 and G2/M phases.
To conﬁrm further that berberine induces cell cycle arrest,
ell cycle checkpoint-related proteins, speciﬁcally phosphorylated-
hk1 (p-Chk1), phosphorylated-Chk2 (p-Chk2), and p21Waf1/Cip1,
ere examined with Western blots. It is known that activated Chk2
nd p21Waf1/Cip1 lead to cell cycle arrest in G1 phase (Chehab et al.,
000; Gartel and Radhakrishnan, 2005; Matsuoka et al., 1998).
ctivated Chk1 phosphorylates and inhibits Cdc25C, thus arrest-
ng cells at G2/M (Matsuoka et al., 1998; Sanchez et al., 1997).
tarting at the 3.125 M,  treatment of HepG2 cells with berber-
ne for 6 h displayed dose-dependent increase in p-Chk1, p-Chk2,
nd p21Waf1/Cip1 (Fig. 4C). Taken together, these data indicate that
erberine induces cell cycle arrest at G1 and G2/M through activa-
ion of Chk1, Chk2, and p21Waf1/Cip1.
.4. The inhibitory effect of goldenseal constituents on Topo I and
I activities
Previously, it was reported that berberine can inhibit topoi-
omerases (Gatto et al., 1996; Kang and Chung, 2002; Kobayashi
t al., 1995), but whether Topo I, Topo II, or both can be so
nhibited remained unclear. In addition, it was not known if the
ther goldenseal alkaloid constituents exert similar effects. Thus,
e investigated the effect of goldenseal constituents on the enzy-
atic activities of Topo I and Topo II in cell free systems. The effect
f ﬁve goldenseal constituents on the Topo I-mediated DNA relax-
tion of supercoiled plasmid DNA pBR322 was studied. As shown
n Fig. 5A, berberine and palmatine at 500 M inhibited the DNAiments. * p < 0.05, ** p < 0.005, and ***p < 0.001 versus the respective G1, S, or G2/M
G2 cells were treated with the indicated concentrations of berberine for 6 h. Treated
pho-Chk1, phosphor-Chk2, and p21Waf1/Cip1. -actin was used as a loading control.
relaxation activity of Topo I (as judged by a decrease in the fraction
of relaxed DNA and an increase in supercoiled DNA), whereas the
other three did not. The inhibitory effects of both berberine and
palmatine were also dose-dependent (Fig. 5B and C).
The effect of goldenseal constituents on Topo II-mediated
decatenation of double-stranded catenated kinetoplast DNA
(kDNA) was  also assessed. At 500 M,  berberine and palmatine sig-
niﬁcantly inhibited Topo II activity as evidenced by reducing the
amount of circular decatenated kDNA and increasing the amount
of catenated kDNA, while canadine showed marginal Topo II inhi-
bition (Fig. 5D). The inhibitory effects of berberine and palmatine
were dose-dependent (Fig. 5E and F). Taken together, these results
clearly demonstrated that berberine and palmatine are inhibitors
of both Topo I and II.
3.5. The DNA damaging effect of berberine is Topo II dependent
but Topo I independent
To investigate the role of Topo I and II in berberine-induced
DNA damage, a lentivirus system was used to establish doxycy-
cline (DOX)-induced silencing of Topo I and II in HepG2 cells. Two
sets of shRNAs, targeting Topo I (sh1-Topo I and sh2-Topo I) or
Topo II (sh1-Topo II and sh2-Topo II), were designed, and all were
shown to down-regulate transcription of their respective targets,
Topo I or Topo II, with efﬁciencies of 67% and 89% for Topo I and
94% and 83% for Topo II (Fig. 6A and B). DNA damage was  inves-
tigated by measuring levels of -H2A.X in HepG2 cells exposed to
0, 50, or 100 M berberine for 6 h after the silencing of Topo I or
II. The Western blotting results showed that silencing Topo II alle-
viated DNA damage (Fig. 6D). In contrast, no signiﬁcant change in
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Fig. 5. Inhibitory effects of goldenseal constituents on topoisomerase activities. Supercoiled DNA relaxation assay for Topo I (A, B) and kDNA decatenation assay for Topo II
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rD,  E). Supercoiled pBR322 plasmid DNA or kDNA was incubated at 37 C for 30 m
onstituents (A, D) or increasing concentrations of berberine and palmatine (B, E);
eparated by electrophoresis on 1% agarose gel, stained with ethidium bromide, a
epresent the densitometric analyses of the results from B and E. Values are means 
-H2A.X was observed in berberine-treated cells after Topo I was
ilenced, compared to the scrambled control (Fig. 6C). These data
uggest that berberine causes DNA breakage via a Topo II-mediated,
ay  not a Topo I-mediated, mechanism.
. Discussion
The use of herbal dietary supplements has become popular in
he United States since the US Congress passed the Dietary Sup-
lement Health and Education Act (DSHEA) in 1994, but despite
eports of human toxicity associated with their use, concerns about
he safety of herbal products have not been adequately addressed.
he mechanisms of toxicity remain unclear for many herbal prod-
cts and data on the identiﬁcation of toxic ingredients in herbal
roducts are also largely lacking. For such reasons, a number of
erbal dietary supplements have been assessed by the NTP for tox-
city and tumorigenicity (Fu et al., 2008; Guo et al., 2008, 2009,
010). Goldenseal root powder was one of the herbal dietary sup-
lements selected for assessment, and the primary ﬁnding of the
TP’s study was that chronic exposure to goldenseal causes an
ncrease in liver tumors in rodents (Dunnick et al., 2011; NTP, 2009).
owever, the mechanism of goldenseal-associated tumorigenic-
ty was entirely unknown and the toxic ingredients in goldenseal
emained to be identiﬁed.h or without Topo I or Topo II enzyme in the presence of the indicated goldenseal
camptothecin) was used as a Topo I positive control inhibitor. DNA samples were
sualized by UV light. RLX, relaxed DNA; SC, supercoiled DNA. Bar graphs C and F
 of three separate experiments. * p < 0.05, ** p < 0.005 versus the DMSO control.
In the present study, we  evaluated DNA damaging capacity
of ﬁve alkaloid constituents in goldenseal and explored poten-
tial molecular mechanisms of induction of the damage. We  used
hepatic cells in our study because the primary target organ of
goldenseal-induced carcinogenicity is liver. We chose HepG2 cells
because they demonstrated increased values in toxicological stud-
ies (Dykens et al., 2008; Guo et al., 2006; Liu and Zeng, 2009;
Nguyen et al., 2013; Wei  et al., 2009), and importantly, the capa-
bility of genetic modiﬁcation (in our case, silencing genes of
interest) provides more opportunities for studying in-depth mech-
anisms. Although the lack of some drug metabolizing genes (as
we demonstrated previously (Guo et al., 2011)) could be problem-
atic for certain speciﬁc studies, it was not a major concern for us
because this current study was  not designed to study the impact of
metabolism on berberine or other constituents. Our data demon-
strated that out of the ﬁve goldenseal alkaloid constituents tested
in vitro, berberine has a relatively high DNA damaging capacity
as measured with the Comet assay (Fig. 2A). Further study showed
that berberine induced DNA double strand breaks evidenced by the
enhancement of cellular levels of -H2A.X (Fig. 2B). Previous stud-
ies suggested that berberine and its metabolites may inhibit activity
of topoisomerases and that there may  be a link between berberine-
induced DNA damage and topoisomerase inhibition (Kang and
Chung, 2002; Kettmann et al., 2004; Kim et al., 1998; Kobayashi
et al., 1995; Li et al., 2000; Qin et al., 2007).
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Fig. 6. Effect of down-regulation of Topo I or Topo II on berberine induced DNA damage. (A, B) Establish HepG2 cells stably express doxycycline (DOX) inducible sh1-Topo
I,  sh2-Topo I, sh1-Topo II, sh2-Topo II, or a scrambled (SC) control. These ﬁve cell lines were incubated with DOX for 3 days followed by continued culture for another 6 h
without DOX; then the decrease in Topo I or Topo II mRNA was assessed by real-time PCR. The results indicated that the mRNA expression levels of Topo I (A) or Topo II (B)
were  signiﬁcantly decreased by DOX induction of the shRNAs. Values were means ± S.D. of three separate experiments. *** p < 0.001 versus the SC controls. (C) sh1-Topo I,
sh2-Topo I, (D) sh1-Topo II, sh2-Topo II, and SC cells were incubated with DOX for 3 days and then treated with berberine at 50 M or 100 M for another 6 h without DOX.
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breated cells were then lysed and subjected to Western blot analyses with an antibo
rom  three repeated experiments.
Topo I and II-targeted inhibitors are commonly classiﬁed as cat-
lytic inhibitors and poisons (Bartek and Lukas, 2003; Larsen et al.,
003; Wilstermann and Osheroff, 2003). Topoisomerases catalytic
nhibitors interact with the free enzyme and inhibit the forma-
ion of topo-DNA complexes, thus blocking all subsequent steps
n the catalytic cycle of the enzymes. In contrast, the topoisome-
ase poisons freeze the normally transient topo-DNA complexes;
ct after the cleavage of DNA by the enzyme and inhibit the reli-
ation. Topoisomerase poisons act by blocking the ligation step of
he cell cycle, thus generating single and double stranded breaks
hat destroy the integrity of the genome. Although some topo-
somerase inhibitors have therapeutic efﬁcacy in human cancer,
he use of topoisomerase inhibitors can also cause secondary
umor formation by interfering with DNA repair processes and
nducing chromosomal aberrations (Ezoe, 2012). Our studies with
opo I-mediated pBR322 relaxation and Topo II-mediated kDNA
ecatenation clearly demonstrated that berberine suppressed the
ctivities of both Topo I and II (Fig. 5).
Berberine possess low afﬁnity of direct binding DNA (Mazzini
t al., 2003; Park et al., 2004), in addition, our data also showed
hat berberine does not act as a DNA intercalator (Supplemental
ig. 2), suggesting that berberine’s DNA damaging effect is unlikely
hrough the direct interaction with DNA.
Most Topo II inhibitors, such as etoposide (Fortune and Osheroff,
000) and emodin (Li et al., 2010), interfere the cleavage and reli-
ation step in the normal action of the enzymes, stabilize cleavable
opo-DNA complexes, and the trigger DNA double strand breaks.
erberine has demonstrated distinct enzyme poisoning activities
y stabilizing topoisomerase II-DNA cleavable complexes (Jeon
t al., 2002). Moreover, when silencing Topo II in HepG2 cells, DNA
ouble strand breaks were effectively suppressed (Fig. 6D), sug-
esting that inhibition of Topo II activity and stabilization of Topo
I-DNA complexes play a critical role in the induction of DNA dou-
le strand breaks and DNA damage may  not be associated withainst -H2A.X. -actin was used as a loading control. Similar results were obtained
inhibition of Topo I, although berberine inhibited the activities of
both Topo I and II in cell free system (Fig. 5).
DNA damage triggers the activation of checkpoint responses
that arrest the cell cycle and stimulate the transcription of genes
that facilitate DNA repair. Ongoing DNA damage leads to genomic
instability that is involved in initiation and promotion of cancer.
Ataxia telangiectasia mutated (ATM) and ataxia telangiectasia and
Rad-3-related (ATR), members of the phoshpoinositide kinases-
related protein family, are two  most important kinases responding
to DNA double strand breaks and subsequent cell cycle arrest (Mei
et al., 2003; Shiloh, 2001). Once activated by DNA damage, ATM
and ATR phosphorylate a number of substrates including Chk1 and
Chk2, which in turn target other proteins to induce cell cycle arrest
and facilitate DNA repair. Chk1 activation requires phosphoryla-
tion at Ser-317 and Ser-345 catalyzed by ATM and/or ATR (Gatei
et al., 2003; Zhao and Piwnica-Worms, 2001). Chk2 is activated
by ATM-mediated phosphorylation at Thr-68 (Bartek and Lukas,
2003). Activation of Chk1 and Chk2 further phosphorylate down-
stream proteins such as Cdc25 family and p53. Phosphorylation
of Cdc25 family contributes to G2/M arrest, while phosphoryla-
tion of p53 enhances the transcription of p21waf1/cip1 and result
in G1 arrest and/or G2/M arrest (Matsuoka et al., 1998; Niculescu
et al., 1998; Sanchez et al., 1997; Waldman et al., 1995). Most
importantly, once ATM and ATR activated, these kinases rapidly
phosphorylate multiple effector molecules at the sites of damage,
such as H2A.X, a variant of the core histone H2A family, to produce
H2A.X, which contributes to nucleosome-formation and serves
as a biomarker of DNA double strand breaks (Ivashkevich et al.,
2012). Our results include induction of p-Chk1, p-Chk2, p21Waf1/Cip1
(Fig. 4C), and -H2A.X (Fig. 2B), and cell cycle arrest (Fig. 4A and B)
indicate there is a cascaded cellular response in response to the
exposure of berberine.
The suggested maximum human oral dose of berberine
for the treatment of diabetes (http://examine.com/supplements/
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erberine) or cardiac dysfunction is 2000 mg  daily (Zeng et al.,
003). Berberine is absorbed from gastrointestinal tract following
ral administration (Deng et al., 2008; Qiu et al., 2008) and it can
e actively transported to the liver (Tsai and Tsai, 2004). Although
ioavailability of berberine is low (0.68%), some co-administered
rugs can enhance its absorption (Chen et al., 2011). Clinical studies
ave shown that the plasma concentration of berberine can reach
o 0.39 mg/l (1.2 M)  after a single oral dose of 300 mg berberine
Ye et al., 2009) and 0.3 mg/l (0.9 M)  after multi-dose oral admin-
stration of 1200–2000 mg  berberine per day for eight weeks (Zeng
t al., 2003). In our studies, toxic effect of berberine became appar-
nt at 3.125 M (Fig. 2), which is close to the plasma concentration
etected in human blood samples. Thus, the use of berberine at the
uggested clinically relevant levels may  carry a risk of DNA damage.
It is worth mentioning that DNA damage was also observed with
ommercial goldenseal products and the extent of DNA damage
as positively correlated with the berberine content, with a cor-
elation coefﬁcient of 0.98 (Fig. 3). Berberine was detected as the
ajor alkaloid component in commercial goldenseal extracts. Our
ata support the notion that berberine is the major contributor to
oldenseal-induced DNA damage and monitoring the concentra-
ion of berberine in goldenseal products can be used to predict the
oxicity of goldenseal.
In conclusion, we demonstrated that berberine, the major gold-
nseal alkaloid constituent, induced DNA damage in liver cells,
nd conﬁrmed that DNA damage effect is via its interaction with
opoisomerase. We  suspect that the DNA damaging ability and
umorigenicity of berberine and goldenseal may  be due in part
o the inhibition of topoisomerase by berberine. The use of gold-
nseal or berberine products may  be not without risk due to this
off-target” toxicity.
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